Alexion Pharmaceuticals, Inc.
Heart disease drug maker reports loss of $1.16 per share
Published in Pharma Investments, Ventures and Law Weekly, November 6th, 2005
For the quarter ended July 31, 2005, Alexion reported revenues of $203,000 compared to $4.15 million for the same period last year. During the fourth quarter last year, the company had recognized a $4 million milestone payment from Procter & Gamble Pharmaceuticals (P&G) related to the APEX-AMI trial.
Total operating expenses for the quarter were $33.83 million compared to $23.37 million in the same quarter last year. The company's research and development expenses for the 3-month period ended July 31, 2005, were $27.62 million...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Acuity Medical
Electrical stimulation device treats age-related macular degeneration - Acusphere, Inc.
Microparticle drug technology developer closes common stock offering - Aditus Medical
Electroporation-focused company expands its intellectual property portfolio - BTG plc
BeneFIX maker projects 10% growth - BioDelivery Sciences International, Inc.
Drug delivery firm closes public offering of 4.4M shares - Bioheart, Inc.
Stem cell therapy company raises $19M in Series D round - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
